fashion -WSS

fashion

author：fashion 2025-09-27 12:34:16 - browse：5

Palm Drive at Stanford University on March 28, 2023 — Palm Drive at the entrance to Stanford University. Brian Frank for STAT

The resignation of Marc Tessier-Lavigne as president of Stanford University following an investigation into irregularities in his past research marks more than just the startling downfall of the leader of one of the nation’s top research powerhouses. The case is likely to have broader repercussions, signaling a tipping point in an ongoing and often contentious debate about how to assign blame and credit in the increasingly collaborative world of research.

Science is a team sport. And while the lab leaders, or principal investigators, often get most of the attention for biomedical breakthroughs, they seldom run experiments. That work is left to postdoctoral researchers, graduate students, and others who peer through microscopes, labor away in mouse rooms, and spend countless hours pipetting. Instead, professors play more of a managerial role, supervising, critiquing, and offering big-picture feedback on the work that goes on in their lab.

It’s a longstanding arrangement, but one that leads to a thorny question when research is challenged: Who’s to blame? STAT put that question to Stanford faculty and students while reporting earlier this year on allegations of image manipulation and other misconduct related to research in Tessier-Lavigne’s lab, as well as researchers at other institutions. The answer varied depending on whom you asked.

Graduate students stressed that since faculty have no qualms using work done in their labs to land grants, win prizes, and build prestige, they should ultimately be accountable for problems with the science done under their supervision. Faculty generally agree, at least in principle, but are often quick to say that there are limits to how closely they can scrutinize their lab’s work, and that team science is in part based on trust. It’s an argument Tessier-Lavigne cited in his own statement about his resignation.

It’s also one he said wasn’t good enough.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： New England Journal of Medicine addresses racist history, slavery

focus

WSS

The Harvard botanist who searched for psychedelics in the Amazon

Alabama hospital puts IVF treatments on hold

He's a Nobel laureate. Critics say he was misleading on Covid

Heart disease and mental health: A look at cardiac psychology

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Alabama frozen embryo ruling has major implications for IVF clinics

Wikipedia

fashion

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

Community Health Systems hospitals under DOJ investigation

Continuity nursing helped my family in our darkest PICU moments

Obesity drugs seen as possible treatment for liver disease MASH

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Fauci’s Covid grilling leads GOP to weigh foreign research rules

How to save PrEP access — and even expand it

STAT readers on older presidents, polypills, Medicare, and more

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

entertainment

Antivenom research: Lessons from HIV applied in search for universal antidote

NIH study of ME/CFS points to clear biological hallmarks

Readout LOUD podcast: live from JPM 2024

Medicare inequities exacerbate Puerto Rico’s health disparities

R1 RCM gets $5.8 billion buyout offer from private equity firm

In utero gene editing: an explainer

Wikipedia

knowledge

focus

explore